by Liz Highleyman for aidsmap
A new therapeutic vaccine for human papillomavirus (HPV), a sexually transmitted virus that can cause anal and genital cancer, appears safe and stimulates an immune response in HIV-positive people, according to a poster presented Monday at the Fourth International AIDS Society Conference on HIV Treatment, Pathogenesis and Prevention in Sydney.
Although two HPV preventive vaccines have now been approved in Europe, it is unclear if those vaccines will have any impact on the incidence of anal or cervical cancer in HIV-positive people already infected with HPV.
An analysis of the FUTURE 1 study of the approved Gardasil HPV vaccine found a 73% efficacy rate against the development of anogenital warts or pre-cancerous or cancerous cell changes in the anus in women during four years of follow-up. However the investigators stressed that the study did not include HIV-positive people, and the protective effect of the vaccine in people with HIV remains unclear.
A therapeutic vaccine against cancer-causing HPV type 16 is being developed by the Australian company CSL. It is designed to prevent the development of neoplasia (pre-cancerous cell changes) by stimulating cellular immune responses to this type of HPV.
The manufacturer chose to test the vaccine in HIV-positive people in order to determine whether it would induce immune responses to HPV in people with moderate immune suppression.
Read the rest.
No comments:
Post a Comment